MabVax Therapeutics Stock Price, News & Analysis (NASDAQ:MBVX)

$0.88 0.01 (1.15 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$0.88
Today's Range$0.85 - $0.92
52-Week Range$0.43 - $3.57
Volume147,742 shs
Average Volume302,027 shs
Market Capitalization$20.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52

About MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company’s product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company’s HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

Receive MBVX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBVX
CUSIPN/A
Phone858-259-9405

Debt

Debt-to-Equity Ratio0.80%
Current Ratio0.54%
Quick Ratio0.54%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales134.82
Cash FlowN/A
Price / CashN/A
Book Value$0.53 per share
Price / Book1.66

Profitability

Trailing EPS($3.63)
Net Income$-17,660,000.00
Net MarginsN/A
Return on Equity-1,574.33%
Return on Assets-188.70%

Miscellaneous

Employees26
Outstanding Shares22,980,000

MabVax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions

What is MabVax Therapeutics' stock symbol?

MabVax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."

How were MabVax Therapeutics' earnings last quarter?

MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter. View MabVax Therapeutics' Earnings History.

Who are some of MabVax Therapeutics' key competitors?

How do I buy MabVax Therapeutics stock?

Shares of MabVax Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MabVax Therapeutics' stock price today?

One share of MabVax Therapeutics stock can currently be purchased for approximately $0.88.

How big of a company is MabVax Therapeutics?

MabVax Therapeutics has a market capitalization of $20.23 million and generates $150,000.00 in revenue each year. The company earns $-17,660,000.00 in net income (profit) each year or ($3.63) on an earnings per share basis. MabVax Therapeutics employs 26 workers across the globe.

How can I contact MabVax Therapeutics?

MabVax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]


MarketBeat Community Rating for MabVax Therapeutics (MBVX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  55
MarketBeat's community ratings are surveys of what our community members think about MabVax Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MabVax Therapeutics (NASDAQ:MBVX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

MabVax Therapeutics (NASDAQ:MBVX) Consensus Price Target History

Price Target History for MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics (NASDAQ:MBVX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2016LaidlawInitiated CoverageBuy$2.50N/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

MabVax Therapeutics (NASDAQ:MBVX) Earnings History and Estimates Chart

Earnings by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics (NASDAQ MBVX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.54)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.69)($1.47)ViewN/AView Earnings Details
5/24/2017Q1 2017($0.81)($0.85)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.77)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.74)($0.86)ViewN/AView Earnings Details
8/11/2016Q2 2016($1.41)($0.89)ViewN/AView Earnings Details
5/9/2016Q1 2016($1.18)($1.11)ViewN/AView Earnings Details
10/30/2015Q3 2015($1.48)ViewN/AView Earnings Details
8/10/2015Q2 2015($0.89)($2.15)ViewN/AView Earnings Details
5/15/2015Q1 2015($46.26)ViewN/AView Earnings Details
5/15/2014Q1 2014($13.62)ViewN/AView Earnings Details
3/10/2014Q4 2013($10.07)ViewN/AView Earnings Details
11/12/2013Q3 2013($14.80)ViewN/AView Earnings Details
8/9/2013Q2 2013($17.76)ViewN/AView Earnings Details
5/10/2013Q1 2013($27.24)ViewN/AView Earnings Details
3/15/2013Q4 2012($39.08)ViewN/AView Earnings Details
11/9/2012Q312($0.78)ViewN/AView Earnings Details
8/10/2012Q2 2012($65.73)ViewN/AView Earnings Details
5/9/2012Q1 2012($74.26)ViewN/AView Earnings Details
2/23/2012Q4 2011($124.48)($81.80)ViewN/AView Earnings Details
11/3/2011Q3 2011($124.48)($94.25)ViewN/AView Earnings Details
8/11/2011Q2 2011($124.48)($106.69)ViewN/AView Earnings Details
5/16/2011Q1 2011($124.48)($124.48)ViewN/AView Earnings Details
2/22/2011Q4 2010($337.87)($133.37)ViewN/AView Earnings Details
11/3/2010Q3 2010($154.71)ViewN/AView Earnings Details
8/6/2010Q2 2010($165.38)ViewN/AView Earnings Details
5/6/2010Q1 2010($177.82)($177.82)ViewN/AView Earnings Details
2/25/2010Q4 2009($213.39)($142.26)ViewN/AView Earnings Details
11/13/2009Q3 2009($195.61)ViewN/AView Earnings Details
8/6/2009Q2 2009($231.17)($188.49)ViewN/AView Earnings Details
5/7/2009Q1 2009($195.61)($257.84)ViewN/AView Earnings Details
2/26/2009Q4 2008($373.43)($12.45)ViewN/AView Earnings Details
11/5/2008Q3 2008($409.00)($245.40)ViewN/AView Earnings Details
8/11/2008Q2 2008($409.00)($453.45)ViewN/AView Earnings Details
5/8/2008Q1 2008($409.00)($328.97)ViewN/AView Earnings Details
2/27/2008Q4 2007($409.00)($435.67)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MabVax Therapeutics (NASDAQ:MBVX) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.01 EPS
Next Year EPS Consensus Estimate: $-2.93 EPS

Dividends

Dividend History for MabVax Therapeutics (NASDAQ:MBVX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MabVax Therapeutics (NASDAQ MBVX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.76%
Institutional Ownership Percentage: 12.87%
Insider Trades by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

MabVax Therapeutics (NASDAQ MBVX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Gregory P HansonInsiderSell41,873$0.92$38,523.16320,013View SEC Filing  
1/16/2018John David HansenCEOSell59,263$0.92$54,521.96536,730View SEC Filing  
1/16/2018Paul F ResnickVPSell3,071$0.92$2,825.3218,333View SEC Filing  
1/16/2018Paul W MaffuidEVPSell38,054$0.92$35,009.68283,703View SEC Filing  
1/12/2018Gregory P HansonCFOSell11,232$0.96$10,782.72478,365View SEC Filing  
1/12/2018John David HansenCEOSell18,582$0.96$17,838.72788,683View SEC Filing  
1/12/2018Paul F ResnickVPSell824$0.96$791.0429,944View SEC Filing  
1/12/2018Paul W MaffuidEVPSell10,207$0.96$9,798.72427,608View SEC Filing  
1/12/2018Philip O LivingstonInsiderSell3,571$0.96$3,428.16293,581View SEC Filing  
1/10/2018Gregory P HansonCFOSell66,550$0.96$63,888.00478,365View SEC Filing  
1/10/2018John David HansenCEOSell110,093$0.96$105,689.28788,683View SEC Filing  
1/10/2018Paul F ResnickVPSell4,879$0.96$4,683.8429,944View SEC Filing  
1/10/2018Paul W MaffuidEVPSell60,478$0.96$58,058.88427,608View SEC Filing  
1/10/2018Philip O LivingstonInsiderSell21,155$0.96$20,308.80293,581View SEC Filing  
4/12/2017John David HansenInsiderSell10,216$2.00$20,432.0061,473View SEC Filing  
4/11/2017John David HansenInsiderSell1,476$2.00$2,952.0072,499View SEC Filing  
4/6/2017John David HansenInsiderSell5,051$2.17$10,960.6777,116View SEC Filing  
3/24/2016Jeffrey V. RavetchDirectorSell131,500$0.60$78,900.00View SEC Filing  
5/29/2015Paul V MaierDirectorBuy5,000$2.30$11,500.00View SEC Filing  
5/22/2015Kenneth M CohenDirectorBuy3,500$2.30$8,050.00View SEC Filing  
12/17/2014Kenneth M CohenDirectorBuy2,500$1.80$4,500.00View SEC Filing  
12/16/2014Gregory P HansonCFOBuy3,000$2.50$7,500.00View SEC Filing  
12/16/2014Robert HoffmanDirectorBuy10,000$2.40$24,000.00View SEC Filing  
9/12/2014Jim J AntonopoulosDirectorSell11,892$6.00$71,352.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MabVax Therapeutics (NASDAQ MBVX) News Headlines

Source:
DateHeadline
Gregory P. Hanson Sells 41,873 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) StockGregory P. Hanson Sells 41,873 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 18 at 9:58 PM
Paul W. Maffuid Sells 38,054 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) StockPaul W. Maffuid Sells 38,054 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 18 at 9:58 PM
Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 59,263 Shares of StockInsider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 59,263 Shares of Stock
www.americanbankingnews.com - January 18 at 9:58 PM
MabVax Therapeutics Holdings, Inc. Provides Business Strategy UpdateMabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
finance.yahoo.com - January 16 at 9:19 AM
MabVax Therapeutics Holdings, Inc. (MBVX) Insider Sells $20,308.80 in StockMabVax Therapeutics Holdings, Inc. (MBVX) Insider Sells $20,308.80 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM
MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in StockMabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM
MabVax Therapeutics Holdings, Inc. (MBVX) EVP Sells $58,058.88 in StockMabVax Therapeutics Holdings, Inc. (MBVX) EVP Sells $58,058.88 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM
Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 18,582 Shares of StockInsider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 18,582 Shares of Stock
www.americanbankingnews.com - January 16 at 6:24 AM
John David Hansen Sells 110,093 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) StockJohn David Hansen Sells 110,093 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 16 at 6:24 AM
Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells 66,550 Shares of StockInsider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells 66,550 Shares of Stock
www.americanbankingnews.com - January 16 at 6:24 AM
Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?
finance.yahoo.com - January 4 at 4:56 PM
Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873
finance.yahoo.com - December 22 at 9:22 AM
BRIEF-MabVax Therapeutics Says Completed Patient Enrollment In Expanded Cohort Of Phase-1 Trial Testing MVT-5873BRIEF-MabVax Therapeutics Says Completed Patient Enrollment In Expanded Cohort Of Phase-1 Trial Testing MVT-5873
www.reuters.com - December 20 at 4:52 PM
BRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Cos Common StockBRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock
www.reuters.com - December 15 at 9:31 AM
MabVax Therapeutics (MBVX) Reports Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 TrialMabVax Therapeutics (MBVX) Reports Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial
www.streetinsider.com - December 14 at 9:18 AM
BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer DrugBRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug
www.reuters.com - December 13 at 5:04 PM
MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung CancersMabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers
finance.yahoo.com - December 13 at 9:28 AM
MabVax Therapeutics Holdings Inc (MBVX): Should The Recent EPS Drop Worry You?MabVax Therapeutics Holdings Inc (MBVX): Should The Recent EPS Drop Worry You?
finance.yahoo.com - December 2 at 9:20 AM
What Does MabVax Therapeutics Holdings Inc’s (MBVX) Share Price Indicate?What Does MabVax Therapeutics Holdings Inc’s (MBVX) Share Price Indicate?
finance.yahoo.com - November 17 at 3:18 PM
MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual MeetingMabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting
finance.yahoo.com - November 14 at 2:59 AM
MabVax Therapeutics Holdings, Inc. (MBVX) Posts  Earnings ResultsMabVax Therapeutics Holdings, Inc. (MBVX) Posts Earnings Results
www.americanbankingnews.com - November 9 at 4:34 PM
MabVax Therapeutics to Present Three Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsMabVax Therapeutics to Present Three Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 27 at 6:22 AM
MabVax Therapeutics Holdings, Inc. Announces $500,000 Registered Direct OfferingMabVax Therapeutics Holdings, Inc. Announces $500,000 Registered Direct Offering
finance.yahoo.com - October 11 at 3:19 PM
MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung CancersMabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers
finance.yahoo.com - October 11 at 3:19 PM
MabVax Stockholders Approve Proposals at Special Meeting of StockholdersMabVax Stockholders Approve Proposals at Special Meeting of Stockholders
finance.yahoo.com - October 4 at 6:48 AM
Novel Preclinical Studies with MabVax Therapeutics HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging CongressNovel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress
finance.yahoo.com - October 3 at 10:24 AM
MabVax Announces Adjournment of Special Meeting of StockholdersMabVax Announces Adjournment of Special Meeting of Stockholders
www.bizjournals.com - September 28 at 6:43 PM
MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct OfferingMabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct Offering
finance.yahoo.com - September 23 at 8:04 AM
Why You Need To Look At This Factor Before Buying MabVax Therapeutics Holdings Inc (MBVX)Why You Need To Look At This Factor Before Buying MabVax Therapeutics Holdings Inc (MBVX)
finance.yahoo.com - September 21 at 5:46 PM
BRIEF-John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings IncBRIEF-John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc
www.reuters.com - September 20 at 6:07 AM
MabVax secures $2M private capital raise; shares down 18%MabVax secures $2M private capital raise; shares down 18%
seekingalpha.com - September 13 at 6:24 AM
MabVax Therapeutics (MBVX) Engages Greenhill & Co. as Advisor for Exploring Strategic AlternativesMabVax Therapeutics (MBVX) Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives
www.streetinsider.com - September 7 at 1:04 AM
BRIEF-Mabvax Therapeutics Holdings, Inc. Announces the closing of $1.3 million registered direct offeringBRIEF-Mabvax Therapeutics Holdings, Inc. Announces the closing of $1.3 million registered direct offering
www.reuters.com - August 22 at 8:48 PM
MabVax Therapeutics (MBVX) to Explore Strategic Alternatives; Closes $1.3M Direct OfferingMabVax Therapeutics (MBVX) to Explore Strategic Alternatives; Closes $1.3M Direct Offering
www.streetinsider.com - August 22 at 8:48 PM
MabVax Therapeutics Holdings, Inc. (MBVX) Releases  Earnings Results, Misses Expectations By $0.78 EPSMabVax Therapeutics Holdings, Inc. (MBVX) Releases Earnings Results, Misses Expectations By $0.78 EPS
www.americanbankingnews.com - August 16 at 10:54 AM
MabVax inks direct $1.3M capital raiseMabVax inks direct $1.3M capital raise
seekingalpha.com - August 15 at 1:19 AM
MabVax to explore strategic alternatives; shares up 1% premarketMabVax to explore strategic alternatives; shares up 1% premarket
seekingalpha.com - July 24 at 1:12 PM
MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic AlternativesMabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives
finance.yahoo.com - July 24 at 1:12 PM
BRIEF-Mabvax Therapeutics reports positive phase 1 results for MVT-2163 immunopet imaging agentBRIEF-Mabvax Therapeutics reports positive phase 1 results for MVT-2163 immunopet imaging agent
www.businessinsider.com - June 15 at 2:42 AM
MabVax Therapeutics (MBVX) Prices 1.342M Share Offering at $1.75/ShMabVax Therapeutics (MBVX) Prices 1.342M Share Offering at $1.75/Sh
www.streetinsider.com - May 16 at 10:36 AM

SEC Filings

MabVax Therapeutics (NASDAQ:MBVX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MabVax Therapeutics (NASDAQ:MBVX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MabVax Therapeutics (NASDAQ MBVX) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.